Comments
Loading...
Adaptimmune Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:ADAP | Benzinga
Adaptimmune Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 13
EPS
$-0.030
Quarterly Revenue
$7.29M
Annual Revenue
(as of Mar 31)
(as of Mar 31)
$179.64M
Analyze the earnings history of Adaptimmune Therapeutics using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADAP | Adaptimmune Therapeutics | $0.24 | — | — | — | $128.23M | — | — | — | 08/11/2025 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.03 | -$0.17 | -$0.03 | 82.35% | $5.68M | $6.55M | $7.29M | 11.22% | 05/13/2025 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.15 | -$0.30 | -100.00% | $231.00K | $8.42M | $3.22M | -61.73% | 03/20/2025 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.18 | -$0.13 | -$0.07 | 46.15% | $7.32M | $11.17M | $40.90M | 266.17% | 11/13/2024 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.12 | -$0.08 | $0.24 | 400.00% | $5.13M | $38.48M | $128.23M | 233.24% | 08/12/2024 | Get Alert |
| ADAP | Adaptimmune Therapeutics | $0.00 | -$0.10 | -$0.18 | -80.00% | $47.60M | $10.73M | $5.68M | -47.08% | 05/15/2024 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.18 | -$0.10 | -$0.24 | -140.00% | $11.03M | $20.47M | $231.00K | -98.87% | 03/06/2024 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.15 | -$0.18 | -20.00% | $7.01M | $10.28M | $7.32M | -28.80% | 11/08/2023 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.13 | -$0.12 | 7.69% | $5.54M | $8.78M | $5.13M | -41.57% | 08/09/2023 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.14 | $0.00 | 100.00% | $3.58M | $4.93M | $47.60M | 865.54% | 05/12/2023 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.25 | -$0.18 | 28.00% | $1.42M | $4.12M | $11.03M | 167.67% | 03/06/2023 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.30 | -$0.24 | -$0.24 | 0.00% | $1.20M | $4.04M | $7.01M | 73.44% | 11/08/2022 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.25 | -$0.28 | -12.00% | $3.10M | $6.00M | $5.54M | -7.70% | 08/04/2022 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.22 | -$0.32 | -45.45% | $434.00K | $3.29M | $3.58M | 8.66% | 05/09/2022 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | $0.14 | -$0.25 | -278.57% | $1.50M | $96.45M | $1.42M | -98.53% | 03/14/2022 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.26 | -$0.30 | -15.38% | $1.19M | $1.37M | $1.20M | -12.19% | 11/04/2021 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.24 | -$0.24 | -$0.24 | 0.00% | $502.00K | $1.36M | $3.10M | 127.57% | 08/09/2021 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.04 | -$0.25 | -$0.24 | 4.00% | $761.00K | $1.83M | $434.00K | -76.28% | 05/06/2021 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.05 | -$0.23 | -$0.24 | -4.35% | $728.00K | $1.98M | $1.50M | -24.14% | 02/25/2021 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.06 | -$0.25 | -$0.24 | 4.00% | $237.00K | $870.00K | $1.19M | 37.13% | 11/05/2020 | Get Alert |
| ADAP | Adaptimmune Therapeutics | -$0.07 | -$0.23 | -$0.24 | -4.35% | $157.00K | $930.00K | $502.00K | -46.02% | 08/06/2020 | Get Alert |
Adaptimmune Therapeutics (ADAP) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q1 | 2025-05-13 | $-0.03 | $-0.17 | 82.3 % |
| Q4 | 2025-03-20 | $-0.30 | $-0.15 | -100.0 % |
| Q3 | 2024-11-13 | $-0.07 | $-0.13 | 46.2 % |
| Q2 | 2024-08-12 | $0.24 | $-0.08 | 400.0 % |
Adaptimmune Therapeutics (ADAP) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q1 | 2025-05-13 | $7.29M | $6.55M | 11.2 % |
| Q4 | 2025-03-20 | $3.22M | $8.42M | -61.7 % |
| Q3 | 2024-11-13 | $40.90M | $11.17M | 266.2 % |
| Q2 | 2024-08-12 | $128.23M | $38.48M | 233.2 % |
FAQ
When is Adaptimmune Therapeutics (NASDAQ:ADAP) reporting earnings?
Adaptimmune Therapeutics (ADAP) is scheduled to report earnings on August 11, 2025. The last reported earnings were for reported on May 13, 2025 for Q1.
What were the latest earnings per share (EPS) for Adaptimmune Therapeutics (NASDAQ:ADAP)?
The Actual EPS was $-0.03, which beat the estimate of $-0.17.
What were Adaptimmune Therapeutics’s (NASDAQ:ADAP) revenues?
The Actual Revenue was $7.3M, which beat the estimate of $6.5M.
Browse earnings estimates, EPS, and revenue on all stocks.
